368 related articles for article (PubMed ID: 29340807)
21. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
Van Stappen T; Vande Casteele N; Van Assche G; Ferrante M; Vermeire S; Gils A
Gut; 2018 May; 67(5):818-826. PubMed ID: 28450388
[TBL] [Abstract][Full Text] [Related]
22. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab.
Yokoyama Y; Sawada K; Aoyama N; Yoshimura N; Sako M; Hirai F; Kashiwagi N; Suzuki Y
J Crohns Colitis; 2020 Sep; 14(9):1264-1273. PubMed ID: 32166331
[TBL] [Abstract][Full Text] [Related]
24. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
25. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
[TBL] [Abstract][Full Text] [Related]
29. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
30. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
[TBL] [Abstract][Full Text] [Related]
31. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
[TBL] [Abstract][Full Text] [Related]
32. Infliximab therapy intensification upon loss of response: Is there an optimal trough level?
Ungar B; Ben-Shatach Z; Ben-Haim G; Yavzori M; Picard O; Fudim E; Kopylov U; Veyrard P; Del Tedesco É; Paul S; Eliakim R; Ben-Horin S; Roblin X
Dig Liver Dis; 2019 Aug; 51(8):1106-1111. PubMed ID: 30928420
[TBL] [Abstract][Full Text] [Related]
33. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
[No Abstract] [Full Text] [Related]
34. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
35. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
[TBL] [Abstract][Full Text] [Related]
36. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
Colman RJ; Rubin DT
J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
38. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
[TBL] [Abstract][Full Text] [Related]
39. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
Kolho KL; Sipponen T
Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
[TBL] [Abstract][Full Text] [Related]
40. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
